{"id":"placebo-iv-infusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Adverse events attributable to placebo effect or infusion procedure (e.g., injection site reactions, mild discomfort)"}]},"_chembl":{"chemblId":"CHEMBL3121562","moleculeType":"Small molecule","molecularWeight":"784.98"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"A placebo is an inert substance administered in a clinical trial or therapeutic context that lacks pharmacological activity. The apparent clinical benefit derives from patient expectation, the therapeutic ritual of administration, and natural disease progression rather than direct molecular action. Placebo IV infusions are typically used as control comparators in randomized controlled trials to establish the efficacy of active investigational drugs.","oneSentence":"Placebo IV infusion contains no active pharmaceutical ingredient and produces therapeutic effects primarily through the placebo effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:29.488Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Used as a control arm in phase 3 clinical trials (specific indication depends on the active comparator drug being tested)"}]},"trialDetails":[{"nctId":"NCT04199104","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-05","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":511},{"nctId":"NCT03969004","phase":"PHASE3","title":"Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2019-06-04","conditions":"Cutaneous Squamous Cell Carcinoma","enrollment":415},{"nctId":"NCT06128629","phase":"PHASE3","title":"MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)","status":"RECRUITING","sponsor":"Intellia Therapeutics","startDate":"2023-12-13","conditions":"Transthyretin Amyloidosis (ATTR) With Cardiomyopathy","enrollment":1200},{"nctId":"NCT06858579","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)","status":"RECRUITING","sponsor":"Dianthus Therapeutics","startDate":"2025-02-10","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":480},{"nctId":"NCT06439082","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-24","conditions":"Sickle Cell Disease","enrollment":315},{"nctId":"NCT07459166","phase":"PHASE2","title":"A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade","status":"NOT_YET_RECRUITING","sponsor":"Clear Scientific, Inc.","startDate":"2026-04","conditions":"Fentanyl Overdose, Fentanyl Poisoning","enrollment":16},{"nctId":"NCT07210515","phase":"PHASE3","title":"Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)","status":"RECRUITING","sponsor":"Ambros Therapeutics, Inc.","startDate":"2026-03","conditions":"Complex Regional Pain Syndrome Type I","enrollment":270},{"nctId":"NCT06533865","phase":"PHASE3","title":"Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-03-19","conditions":"FHA (Functional Hypothalamic Amenorrhea)","enrollment":114},{"nctId":"NCT03914612","phase":"PHASE3","title":"Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-22","conditions":"Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma","enrollment":813},{"nctId":"NCT06132256","phase":"PHASE2","title":"MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Syndax Pharmaceuticals","startDate":"2023-12-11","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":145},{"nctId":"NCT07273071","phase":"PHASE4","title":"Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections: N-Acetylcysteine","status":"NOT_YET_RECRUITING","sponsor":"Theis S. Itenov","startDate":"2026-07","conditions":"Sepsis, Acute Infection, Severe Infection","enrollment":360},{"nctId":"NCT04251533","phase":"PHASE3","title":"Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-08","conditions":"Triple Negative Breast Neoplasms","enrollment":137},{"nctId":"NCT06290141","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-08-21","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":160},{"nctId":"NCT05039840","phase":"PHASE2","title":"Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2021-11-10","conditions":"Systemic Lupus Erythematosus","enrollment":109},{"nctId":"NCT06290128","phase":"PHASE3","title":"A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-07-12","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic","enrollment":140},{"nctId":"NCT07492771","phase":"PHASE1","title":"MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"MicrobiotiX Co., Ltd","startDate":"2026-03","conditions":"Pneumonia - Bacterial, Pseudomonas Aeruginosa Infection","enrollment":18},{"nctId":"NCT05139316","phase":"PHASE3","title":"A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)","status":"COMPLETED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2021-11-08","conditions":"Glycogen Storage Disease Type IA","enrollment":49},{"nctId":"NCT05072314","phase":"PHASE3","title":"Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial","status":"RECRUITING","sponsor":"Monash University","startDate":"2022-07-27","conditions":"Breast Cancer, Breast Cancer Female, Breast Conserving Surgery","enrollment":4300},{"nctId":"NCT07493577","phase":"PHASE1, PHASE2","title":"Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)","status":"NOT_YET_RECRUITING","sponsor":"Dr David Hasan, M.D.","startDate":"2026-07-23","conditions":"Aneurysmal Subarachnoid Hemorrhage","enrollment":82},{"nctId":"NCT07493785","phase":"PHASE2, PHASE3","title":"Dexmedetomidine for Invasive Ventilation In the NEOnate","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2026-06-01","conditions":"Invasive Ventilation, Infant Pain, Infant Discomfort","enrollment":246},{"nctId":"NCT06830798","phase":"PHASE3","title":"Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-02-24","conditions":"Delayed Graft Function, DGF, Kidney Transplant","enrollment":450},{"nctId":"NCT05447559","phase":"PHASE4","title":"Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study","status":"RECRUITING","sponsor":"Monash University","startDate":"2023-02-07","conditions":"Surgical Site Infection","enrollment":9180},{"nctId":"NCT07211958","phase":"PHASE3","title":"Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation","status":"RECRUITING","sponsor":"Syndax Pharmaceuticals","startDate":"2025-11-25","conditions":"Acute Myeloid Leukemias","enrollment":468},{"nctId":"NCT07173751","phase":"PHASE3","title":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-10-30","conditions":"Breast Neoplasms","enrollment":558},{"nctId":"NCT04107727","phase":"PHASE2","title":"Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2019-09-05","conditions":"Acute Myeloid Leukemia","enrollment":273},{"nctId":"NCT07221474","phase":"PHASE2","title":"A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-12","conditions":"Squamous Non-small Cell Lung Cancer","enrollment":180},{"nctId":"NCT07314060","phase":"PHASE2","title":"A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2026-03-19","conditions":"Generalized Pustular Psoriasis","enrollment":36},{"nctId":"NCT06337838","phase":"PHASE3","title":"Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial","status":"RECRUITING","sponsor":"Hamilton Health Sciences Corporation","startDate":"2025-06-09","conditions":"Chronic Kidney Diseases, Acute Kidney Injury, Bleeding","enrollment":100},{"nctId":"NCT07409272","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2026-02-17","conditions":"Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":614},{"nctId":"NCT06077760","phase":"PHASE3","title":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-06","conditions":"Non-small Cell Lung Cancer","enrollment":868},{"nctId":"NCT06466135","phase":"PHASE2","title":"Study of WAL0921 in Patients With Glomerular Kidney Diseases","status":"RECRUITING","sponsor":"Walden Biosciences","startDate":"2024-07-02","conditions":"Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease","enrollment":96},{"nctId":"NCT06623422","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-10-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":680},{"nctId":"NCT04003636","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-09-24","conditions":"Biliary Tract Carcinoma","enrollment":1069},{"nctId":"NCT06269393","phase":"PHASE3","title":"A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2024-01-01","conditions":"Thyroid Associated Ophthalmopathy","enrollment":53},{"nctId":"NCT06396065","phase":"PHASE3","title":"Phase III Study of AK112 for NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Summit Therapeutics","startDate":"2023-05-04","conditions":"Non-Squamous Non-small Cell Lung Cancer","enrollment":420},{"nctId":"NCT07362446","phase":"PHASE2","title":"Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction","status":"NOT_YET_RECRUITING","sponsor":"Nyrada Pty Ltd","startDate":"2026-04-16","conditions":"Myocardial Infarction, Reperfusion Injury, AMI","enrollment":300},{"nctId":"NCT07088068","phase":"PHASE3","title":"A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-08-06","conditions":"Type 1 Diabetes Mellitus","enrollment":723},{"nctId":"NCT05075824","phase":"PHASE2","title":"A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-09","conditions":"Sickle Cell Disease","enrollment":90},{"nctId":"NCT07487545","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous Infusion","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2026-03-31","conditions":"Healthy","enrollment":52},{"nctId":"NCT07486934","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of DYNE-101 in Participants With Myotonic Dystrophy Type 1","status":"NOT_YET_RECRUITING","sponsor":"Dyne Therapeutics","startDate":"2026-04","conditions":"Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy","enrollment":150},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT07488832","phase":"NA","title":"Intravenous Lidocaine Infusion in Lumbar Fusion Surgery","status":"NOT_YET_RECRUITING","sponsor":"Ankara City Hospital Bilkent","startDate":"2026-03-20","conditions":"Lumbar Fusion Surgery","enrollment":110},{"nctId":"NCT05996835","phase":"PHASE2","title":"Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-18","conditions":"Acute Kidney Injury Due to Sepsis","enrollment":320},{"nctId":"NCT07024823","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-09","conditions":"Chronic Kidney Disease","enrollment":124},{"nctId":"NCT07224711","phase":"PHASE4","title":"The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2026-07-01","conditions":"Pain, Post Operative Analgesia, Opioid Consumption, Postoperative","enrollment":2290},{"nctId":"NCT05285891","phase":"PHASE4","title":"Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-01-12","conditions":"Multiple Sclerosis","enrollment":123},{"nctId":"NCT04763343","phase":"PHASE3","title":"Ketamine Treatment of Youth Suicide Attempters","status":"RECRUITING","sponsor":"Tatiana Falcone, MD","startDate":"2022-06-27","conditions":"Suicide, Attempted","enrollment":60},{"nctId":"NCT05488340","phase":"PHASE2","title":"A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)","status":"RECRUITING","sponsor":"Locus Biosciences","startDate":"2022-07-13","conditions":"Urinary Tract Infections","enrollment":318},{"nctId":"NCT05421858","phase":"PHASE3","title":"A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.","status":"RECRUITING","sponsor":"Basilea Pharmaceutica","startDate":"2024-12-11","conditions":"Candidemia, Candidiasis, Invasive","enrollment":450},{"nctId":"NCT04191096","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-12","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":1251},{"nctId":"NCT06229483","phase":"PHASE3","title":"The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies","status":"RECRUITING","sponsor":"Stephen Lownie","startDate":"2024-04-03","conditions":"Brain Tumor, Bleeding","enrollment":102},{"nctId":"NCT06282588","phase":"PHASE2, PHASE3","title":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers","status":"RECRUITING","sponsor":"Cancer Research Antwerp","startDate":"2023-12-13","conditions":"Prostate Cancer","enrollment":493},{"nctId":"NCT06589986","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-09-17","conditions":"Moderately to Severely Active Ulcerative Colitis","enrollment":400},{"nctId":"NCT07048314","phase":"PHASE1, PHASE2","title":"Stem Cells for Erectile Dysfunction Post RALP","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-03-10","conditions":"Erectile Dysfunction, Prostate Cancer","enrollment":40},{"nctId":"NCT06291376","phase":"PHASE3","title":"Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-03-29","conditions":"Immunoglobulin A Nephropathy, IgAN","enrollment":510},{"nctId":"NCT07462819","phase":"PHASE1","title":"A Study to Evaluate the Safety and Tolerability of Intravenous Stemis™ in Elderly Subjects With Mild to Moderate Frailty Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Ji Yan Biomedical Co., Ltd.","startDate":"2026-04","conditions":"Frailty Syndrome","enrollment":12},{"nctId":"NCT07218380","phase":"PHASE3","title":"A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-12-12","conditions":"Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis","enrollment":450},{"nctId":"NCT06995820","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-06","conditions":"Healthy","enrollment":136},{"nctId":"NCT07392372","phase":"PHASE1","title":"A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2026-02-09","conditions":"HIV -1 Infection","enrollment":61},{"nctId":"NCT03875235","phase":"PHASE3","title":"Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-04-16","conditions":"Biliary Tract Neoplasms","enrollment":810},{"nctId":"NCT04899908","phase":"PHASE2","title":"Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-09-15","conditions":"Brain Cancer, Brain Metastases, Melanoma","enrollment":134},{"nctId":"NCT06611111","phase":"EARLY_PHASE1","title":"Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease","status":"RECRUITING","sponsor":"State University of New York - Upstate Medical University","startDate":"2025-02-03","conditions":"Post-Treatment Lyme Disease","enrollment":44},{"nctId":"NCT06795893","phase":"","title":"The Anifrolumab PRIM Program","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-07","conditions":"Systemic Lupus Erythematosus","enrollment":240},{"nctId":"NCT04379635","phase":"PHASE3","title":"Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2020-05-29","conditions":"Non Small Cell Lung Cancer","enrollment":453},{"nctId":"NCT04639050","phase":"PHASE1, PHASE2","title":"Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-03-15","conditions":"Alzheimers Disease","enrollment":241},{"nctId":"NCT06935357","phase":"PHASE3","title":"A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)","status":"RECRUITING","sponsor":"Biogen","startDate":"2025-05-08","conditions":"Immunoglobulin A Nephropathy (IgAN)","enrollment":454},{"nctId":"NCT06789861","phase":"PHASE1","title":"A First in Human Study of TT5 in Single and Multiple Ascending Doses in Healthy Volunteers and Surgical Patients","status":"RECRUITING","sponsor":"Tafalgie Therapeutics","startDate":"2025-05-23","conditions":"Pain","enrollment":94},{"nctId":"NCT05746559","phase":"PHASE3","title":"ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2023-04-06","conditions":"Chronic Kidney Disease, CKD, Cardiac Disease","enrollment":736},{"nctId":"NCT07184801","phase":"PHASE3","title":"Safety and Efficacy of Dexmedetomidate vs. Midazolam for Procedural Sedation During Medical Thoracoscopy","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2025-10-01","conditions":"Medical Thoracoscopy","enrollment":56},{"nctId":"NCT05907096","phase":"PHASE2","title":"ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function","status":"ACTIVE_NOT_RECRUITING","sponsor":"argenx","startDate":"2024-02-17","conditions":"Delayed Graft Function","enrollment":103},{"nctId":"NCT07219043","phase":"PHASE2","title":"A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation","status":"RECRUITING","sponsor":"Biogen","startDate":"2026-01-05","conditions":"Microvascular Inflammation","enrollment":81},{"nctId":"NCT07024641","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection","status":"RECRUITING","sponsor":"GigaGen, Inc.","startDate":"2024-11-13","conditions":"Hepatitis B Virus Infection","enrollment":48},{"nctId":"NCT06599307","phase":"PHASE2","title":"The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis","status":"RECRUITING","sponsor":"Cairo University","startDate":"2024-08-01","conditions":"Secondary Progressive Multiple Sclerosis (SPMS)","enrollment":46},{"nctId":"NCT07287982","phase":"PHASE2","title":"A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy","status":"RECRUITING","sponsor":"argenx","startDate":"2025-12-19","conditions":"Spinal Muscular Atrophy (SMA)","enrollment":60},{"nctId":"NCT06699849","phase":"PHASE2","title":"Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2025-07-10","conditions":"Sickle Cell Disease Vaso-occlusive Crisis","enrollment":70},{"nctId":"NCT02504372","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-06","conditions":"Non-small Cell Lung Cancer","enrollment":1177},{"nctId":"NCT03100149","phase":"PHASE2","title":"A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-06-27","conditions":"Parkinson's Disease","enrollment":316},{"nctId":"NCT04404283","phase":"PHASE3","title":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-08-20","conditions":"Diffuse Large B-cell Lymphoma","enrollment":238},{"nctId":"NCT04512235","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-11-03","conditions":"AL Amyloidosis","enrollment":281},{"nctId":"NCT04504825","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-08-25","conditions":"AL Amyloidosis","enrollment":125},{"nctId":"NCT03466411","phase":"PHASE2, PHASE3","title":"A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-13","conditions":"Crohn's Disease","enrollment":1409},{"nctId":"NCT06659029","phase":"","title":"Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-01","conditions":"Systemic Lupus Erythematosus","enrollment":442},{"nctId":"NCT06819891","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-05-12","conditions":"Moderately to Severely Active Crohns Disease","enrollment":425},{"nctId":"NCT07473128","phase":"PHASE3","title":"Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Pharmacosmos A/S","startDate":"2026-03-31","conditions":"Limited Stage Small Cell Lung Cancer","enrollment":120},{"nctId":"NCT05065424","phase":"PHASE4","title":"Premedication for Less Invasive Surfactant Administration Study (PRELISA)","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-04-06","conditions":"Respiratory Distress Syndrome, Newborn","enrollment":58},{"nctId":"NCT04119050","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-08-15","conditions":"Warm Autoimmune Hemolytic Anemia","enrollment":118},{"nctId":"NCT05612178","phase":"PHASE1","title":"A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-07-26","conditions":"HIV-1","enrollment":105},{"nctId":"NCT06345729","phase":"PHASE3","title":"A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-24","conditions":"Non-small Cell Lung Cancer","enrollment":600},{"nctId":"NCT06585774","phase":"PHASE3","title":"A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-01-21","conditions":"Chronic Graft-versus-host-disease","enrollment":240},{"nctId":"NCT06767527","phase":"PHASE3","title":"AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-02-07","conditions":"Triple-Negative Breast Cancer (TNBC)","enrollment":416},{"nctId":"NCT05879718","phase":"PHASE2","title":"A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2023-07-07","conditions":"Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous","enrollment":8},{"nctId":"NCT05912517","phase":"PHASE3","title":"A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-12-20","conditions":"Hemolytic Disease of the Fetus and Newborn","enrollment":120},{"nctId":"NCT05523323","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-10-30","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":112},{"nctId":"NCT02726711","phase":"PHASE1","title":"Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University","startDate":"2016-04","conditions":"Multiple System Atrophy, Orthostatic Hypotension, Supine Hypertension","enrollment":2},{"nctId":"NCT06736990","phase":"PHASE2","title":"A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Calluna Pharma AS","startDate":"2025-06-20","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":150},{"nctId":"NCT07007312","phase":"PHASE3","title":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2025-09-26","conditions":"Acute Myeloid Leukemia (AML)","enrollment":1300},{"nctId":"NCT05327114","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-09-23","conditions":"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating","enrollment":201},{"nctId":"NCT07020832","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation","status":"RECRUITING","sponsor":"Apellis Pharmaceuticals, Inc.","startDate":"2026-02","conditions":"Delayed Graft Function, End Stage Renal Disease, Deceased Donor Kidney Transplant","enrollment":320},{"nctId":"NCT04838301","phase":"PHASE2","title":"Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2023-08-15","conditions":"Alzheimer Dementia, Late Onset Alzheimer Disease, Neurodegenerative Diseases","enrollment":100},{"nctId":"NCT04468659","phase":"PHASE3","title":"AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2020-07-14","conditions":"Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease","enrollment":1400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo IV Infusion","genericName":"Placebo IV Infusion","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo IV infusion contains no active pharmaceutical ingredient and produces therapeutic effects primarily through the placebo effect. Used for Used as a control arm in phase 3 clinical trials (specific indication depends on the active comparator drug being tested).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}